Cassava Sciences reported $3.37M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Abbott USD 4.27B 669M Sep/2026
Amgen USD 1.68B 40M Sep/2026
Biogen USD 752M 42.3M Sep/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Cassava Sciences USD 3.37M 521K Jun/2026
Eisai JPY 120.4B 5.58B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Geron USD 35.7M 3.16M Sep/2026
J&J USD 6.25B 168M Sep/2026
Merck USD 2.86B 25M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 3.28B 132M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026